DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus

Journal of Infectious Diseases

Volumn 200, Issue 2, 2009, Pages 181-190

  Szécsi, Judit ^a,b,c   Gabriel, Gülsah ^d,e   Edfeldt, Gabriella ^a,b,c   Michelet, Maud ^a,b,c   Klenk, Hans Dieter ^d   Cosset, François Loïc ^a,b,c  

^a University Lyon i   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITÉ DE LYON   (France)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE; DNA VACCINE; HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DNA IMMUNIZATION; EXPRESSION VECTOR; GENE CONSTRUCT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N1; INFLUENZA VIRUS A H7N7; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS PARTICLE;

EID: 67650667799     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599840     Document Type: Article

References (50)

1. Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine 2007; 25:3062-5.
2. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
3. Lewis DB. Avian flu to human influenza. Annu Rev Med 2006; 57: 139-54.
4. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007;7:267-78.
5. Cox RJ, Brokstad KA, Ogra R Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59: 1-15.
6. Jennings LC, Monto AS, Chan PKS, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
7. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002; 20:3165-70.
8. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159-67.
9. Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25:3871-8.
10. Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008; 26:5393-9.
11. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000; 18:2592-9.
12. Qiu M, Fang F, Chen Y, et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 2006; 343:1124-31.
13. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.
14. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-60.
15. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11:438-44.
16. Bellier B, Dalba C, Clerc B, et al. DNA vaccines encoding retrovirusbased virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006; 24:2643-55.
17. Clarke BE, Newton SE, Carroll AR, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987; 330:381-4.
18. Boisgerault F, Moron G, Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 2002; 1:101-9.
19. Dalba C, Bellier B, Kasahara N, Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 2007; 15:457-66.
20. Fagan EA, Williams R, Eddleston AL. Hepatitis B vaccine: responder status and timing of additional booster doses. Lancet 1987; 2:561.
21. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent Ll virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
22. Szecsi J, Boson B, Johnsson P, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 2006; 3:70.
23. Haynes JR, Dokken L, Wiley JA, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009; 27:530-41.
24. Ferrera F, La Cava A, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann NY Acad Sei 2007; 1110:99-111.
25. Rajcani J, Mosko T, Rezuchova I. Current developments in viral DNA vaccines: shall they solve the unsolved? Rev Med Virol 2005; 15:303-25.
26. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-88.
27. Hatziioannou T, Valsesia-Wittmann S, Russell SJ, Cosset FL. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 1998; 72:5313-7.
28. Sandrin V, Boson B, Salmon P, et al. Lentiviral vectors pseudotyped with a modified RDl 14 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and non-human primates. Blood 2002; 100:823-32.
29. Lin AH, Cannon PM. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res 2002; 83:43-56.
30. Komar AA, Hatzoglou M. Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem 2005; 280:23425-8.
31. Negre D, Mangeot PE, Duisit G, et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 2000; 7:1613-23.
32. Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sei USA 2005; 102:18590-5.
33. Yoshinaka Y, Ishigame K, Ohno T, Kageyama S, Shibata K, Luftig RB. Preparations enriched for "immature" murine leukemia virus particles that remain in tissue culture fluids are deficient in Pr65gag proteolyic activity. Virology 1980; 100:130-40.
34. Ohuchi M, Cramer A, Vey M, Ohuchi R, Garten W, Klenk HD. Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol 1994; 68:920-6.
35. Swanstrom R, J.W Wills. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1997: 263-334.
36. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 1996; 77(Pt 7):1483-7.
37. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006; 194(Suppl 2):S111-8.
38. Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000; 54:210-8.
39. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines 2008; 7:241-7.
40. Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008; 22:279-92.
41. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008; 3:e1501.
42. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175-91.
43. Tuteja R. DNA vaccines: a ray of hope. Crit Rev Biochem Mol Biol 1999; 34:1-24.
44. Russell RJ, Gamblin SJ, Haire LF, et al. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology 2004; 325:287-96.
45. Gocnik M, Fislova T, Sládkova T, Mucha V, Kostolansky F, Vareckova E. Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol 2007; 88:951-5.
46. Gabriel G, Gam H, Wegmann M, et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 2008; 26:956-65.
47. Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008;3:e2517.
48. Campitelli L, Mogavero E, De Marco MA, et al. Interspecies transmission of an H7N3 influenza virus from wild birds to intensively reared domestic poultry in Italy. Virology 2004; 323:24-36.
49. Demi L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005; 42:259-77.
50. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset F-L. Retroviral display of functional binding domains fused to the amino-terminus of influenza haemagglutinin. Human Gene Therapy 1999; 10:1533-44.